471 related articles for article (PubMed ID: 17605814)
1. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
3. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
[TBL] [Abstract][Full Text] [Related]
4. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
Harmon CS; DePrimo SE; Raymond E; Cheng AL; Boucher E; Douillard JY; Lim HY; Kim JS; Lechuga MJ; Lanzalone S; Lin X; Faivre S
J Transl Med; 2011 Jul; 9():120. PubMed ID: 21787417
[TBL] [Abstract][Full Text] [Related]
5. Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Diekstra MH; Fritsch A; Kanefendt F; Swen JJ; Moes D; Sörgel F; Kinzig M; Stelzer C; Schindele D; Gauler T; Hauser S; Houtsma D; Roessler M; Moritz B; Mross K; Bergmann L; Oosterwijk E; Kiemeney LA; Guchelaar HJ; Jaehde U
CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):604-613. PubMed ID: 28571114
[TBL] [Abstract][Full Text] [Related]
6. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
Norden-Zfoni A; Desai J; Manola J; Beaudry P; Force J; Maki R; Folkman J; Bello C; Baum C; DePrimo SE; Shalinsky DR; Demetri GD; Heymach JV
Clin Cancer Res; 2007 May; 13(9):2643-50. PubMed ID: 17473195
[TBL] [Abstract][Full Text] [Related]
7. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.
Vroling L; van der Veldt AA; de Haas RR; Haanen JB; Schuurhuis GJ; Kuik DJ; van Cruijsen H; Verheul HM; van den Eertwegh AJ; Hoekman K; Boven E; van Hinsbergh VW; Broxterman HJ
Angiogenesis; 2009; 12(1):69-79. PubMed ID: 19212818
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
Yuasa T; Takahashi S; Hatake K; Yonese J; Fukui I
Cancer Sci; 2011 Nov; 102(11):1949-57. PubMed ID: 21812860
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
10. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
Motzer RJ; Michaelson MD; Redman BG; Hudes GR; Wilding G; Figlin RA; Ginsberg MS; Kim ST; Baum CM; DePrimo SE; Li JZ; Bello CL; Theuer CP; George DJ; Rini BI
J Clin Oncol; 2006 Jan; 24(1):16-24. PubMed ID: 16330672
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
[TBL] [Abstract][Full Text] [Related]
12. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.
Paule B; Bastien L; Deslandes E; Cussenot O; Podgorniak MP; Allory Y; Naïmi B; Porcher R; de La Taille A; Menashi S; Calvo F; Mourah S
PLoS One; 2010 May; 5(5):e10715. PubMed ID: 20502715
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer.
van der Veldt AA; Vroling L; de Haas RR; Koolwijk P; van den Eertwegh AJ; Haanen JB; van Hinsbergh VW; Broxterman HJ; Boven E
Int J Cancer; 2012 Aug; 131(4):E484-93. PubMed ID: 21953673
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
Kontovinis LF; Papazisis KT; Touplikioti P; Andreadis C; Mouratidou D; Kortsaris AH
BMC Cancer; 2009 Mar; 9():82. PubMed ID: 19284623
[TBL] [Abstract][Full Text] [Related]
15. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.
Porta C; Paglino C; Imarisio I; Ganini C; Sacchi L; Quaglini S; Giunta V; De Amici M
Oncology; 2013; 84(2):115-22. PubMed ID: 23154434
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
[TBL] [Abstract][Full Text] [Related]
18. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Hudes GR; Figlin RA; Martini JF; English PA; Huang X; Valota O; Williams JA
Cancer Chemother Pharmacol; 2014 Oct; 74(4):739-50. PubMed ID: 25100134
[TBL] [Abstract][Full Text] [Related]
19. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib.
Gruenwald V; Beutel G; Schuch-Jantsch S; Reuter C; Ivanyi P; Ganser A; Haubitz M
BMC Cancer; 2010 Dec; 10():695. PubMed ID: 21194438
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
Khosravan R; Motzer RJ; Fumagalli E; Rini BI
Clin Pharmacokinet; 2016 Oct; 55(10):1251-1269. PubMed ID: 27154065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
